Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hepatitis C, Chronic

ClinicalTrials.gov lists 907 trials for Hepatitis C, Chronic or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 107.

MeSH D019698 Infections C01 C06 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 82 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 182 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 182 Phase 4 Phase 4 144 Not applicable Not applicable 55 Observational Observational 214 Phase 1 Phase 1 82 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 182 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 182 Phase 4 Phase 4 144 Not applicable Not applicable 55 Observational Observational 214

Trials per phase

1 more section with rows

907 of the 907 trials are tagged with Hepatitis C, Chronic itself; the rest are tagged with a narrower condition beneath it.

Get the Hepatitis C, Chronic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hepatitis C, Chronic trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 85

1997: 1 trials (Phase 3 1) 1999: 1 trials (Phase 4 1) 2000: 7 trials (Observational 2, Phase 3 3, Phase 2 2) 2001: 9 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2002: 18 trials (Phase 4 6, Phase 3 9, Phase 2 3) 2003: 25 trials (Observational 2, Not applicable 1, Phase 4 11, Phase 3 5, Phase 2 2, Phase 1/2 4) 2004: 29 trials (Observational 6, Phase 4 8, Phase 3 8, Phase 2 5, Phase 1/2 2) 2005: 63 trials (Observational 17, Not applicable 3, Phase 4 16, Phase 3 11, Phase 2 15, Phase 1 1) 2006: 50 trials (Observational 10, Not applicable 1, Phase 4 14, Phase 3 9, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 4) 2007: 59 trials (Observational 12, Not applicable 1, Phase 4 14, Phase 3 6, Phase 2/3 2, Phase 2 15, Phase 1/2 2, Phase 1 7) 2008: 48 trials (Observational 8, Not applicable 3, Phase 4 6, Phase 3 8, Phase 2 12, Phase 1/2 4, Phase 1 7) 2009: 46 trials (Observational 11, Not applicable 2, Phase 4 6, Phase 3 6, Phase 2 12, Phase 1/2 2, Phase 1 7) 2010: 35 trials (Observational 14, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 9, Phase 1 4) 2011: 81 trials (Observational 14, Not applicable 2, Phase 4 11, Phase 3 18, Phase 2 25, Phase 1/2 2, Phase 1 9) 2012: 85 trials (Observational 17, Not applicable 5, Phase 4 4, Phase 3 25, Phase 2/3 2, Phase 2 18, Phase 1/2 1, Phase 1 13) 2013: 57 trials (Observational 4, Not applicable 3, Phase 4 6, Phase 3 14, Phase 2/3 2, Phase 2 17, Phase 1/2 1, Phase 1 10) 2014: 43 trials (Observational 8, Not applicable 3, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 8, Phase 1/2 2, Phase 1 4) 2015: 59 trials (Observational 18, Not applicable 1, Phase 4 7, Phase 3 17, Phase 2/3 3, Phase 2 11, Phase 1/2 1, Phase 1 1) 2016: 52 trials (Observational 16, Not applicable 7, Phase 4 9, Phase 3 10, Phase 2 8, Phase 1 2) 2017: 41 trials (Observational 13, Not applicable 5, Phase 4 8, Phase 3 9, Phase 2/3 2, Phase 2 2, Phase 1 2) 2018: 29 trials (Observational 13, Not applicable 3, Phase 4 4, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1 3) 2019: 30 trials (Observational 15, Not applicable 5, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2020: 13 trials (Observational 4, Not applicable 2, Phase 4 3, Phase 1/2 1, Phase 1 3) 2021: 5 trials (Observational 3, Phase 4 1, Phase 1/2 1) 2022: 6 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 1 1) 2023: 4 trials (Observational 3, Phase 2 1) 2024: 2 trials (Observational 2) 2025: 1 trials (Phase 3 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 1
2024 2
2023 4
2022 6
2021 5
2020 13
2019 30
2018 29
2017 41

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 32 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 728 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hepatitis C, Chronic trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 82
Phase 1/2 26
Phase 2 182
Phase 2/3 19
Phase 3 182
Phase 4 144
Not applicable 55
Observational 214
Expanded access 3

How many Hepatitis C, Chronic trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 3
Enrolling by invitation 1
Active, not recruiting 5
Completed 692
Approved for marketing 1

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hepatitis C, Chronic trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Merck Sharp & Dohme LLC 107
Hoffmann-La Roche 82
AbbVie 71
Gilead Sciences 34
Boehringer Ingelheim 18

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Hepatitis C, Chronic? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEGinterferon alfa-2a 105
Peginterferon Alfa-2B 74
Boceprevir 24
TMC435 24
Daclatasvir 18

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 331
Sofosbuvir, Sovaldi 38
PEGASYS [peginterferon alfa-2a] 30
Telaprevir 22
dasabuvir 8 weeks 19

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hepatitis C, Chronic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Anaemia 432 69
Pneumonia 229 68
ANAEMIA 114 37
Depression 114 46
Pyrexia 112 39

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hepatitis C, Chronic? (1,421)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial. JAMA network open 2026 Yes
No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025 Yes
Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation. The Journal of infectious diseases 2025 Yes
Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025 Yes
A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy. Inflammopharmacology 2025 Yes

Showing 5 of 1,421 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages